In an NGS study of 526 CRC tumor samples, mutations in the TP53 and KRAS genes were found to be frequent, whereas mutations in PIK3CA often coexisted with KRAS, NRAS, or BRAF mutations (39). This evidence concerns the gene KRAS and neoplasm.